Big Pharma
14 May 2026 Isomorphic Labs said the funding round, led by venture firm Thrive Capital, would be used to further its drug design engine and support hiring targets.
Latest Features
Asia
The clash between one of India’s largest B2B marketplaces and the country’s drugs regulator challenges the “passive” position of such platforms with regards to allegedly unlawful pharmaceutical listings, says Aarti Aggarwal of Remfry & Sagar.
Europe
A number of ongoing legislative processes are likely to significantly impact the life sciences industry this year, writes Jackie Mulryne of Morgan Lewis.
Europe
The High Court’s ruling clarifies aspects of the SPC waiver but leaves unresolved questions relating to export-country rights and confidentiality, say Claire Phipps-Jones and Luke Norton of Bristows.
Americas
Companies that integrate data rights into their IP strategy with a holistic approach will lead in innovation while minimising risk, says Terri Shieh-Newton of Mintz.
Europe
With EU trilogues deadlocked over the package, the future of drug exclusivities and access-linked obligations hangs in the balance. Jackie Mulryne and Paul Ranson of Morgan Lewis pinpoint the flashpoints to watch as negotiators push for a year-end deal.
Big Pharma
Clinical trials create a patent paradox. With EPO case law rapidly reshaping the 'expectation of success' test—most recently T136/24—the line between innovation and obviousness is blurred. Amanda Simons of J A Kemp offers drafting strategies to secure protection for your downstream innovations.
Americas
Parties impacted by exclusion orders need to carefully weigh their options for seeking clarity or rulings on redesigns, explain Daniel Muino and Charles Provine from Morrison Foerster.
Europe
As Big Pharma stalls investment in the UK, the government urgently needs to return to the negotiating table to salvage a key growth area, writes Tim Belcher of EIP.
More News
5 May 2026 John Ward, vice president and associate general counsel of trademarks at Moderna, chats with Tom Phillips at INTA 2026.
30 April 2026 The company’s rivals convinced an EPO appeals board to revoke a patent that had been used in litigation against them over Comirnaty.
28 April 2026 An event for IP, legal and compliance leaders to address the growing threat of trade secret misappropriation heads to San Jose.
24 April 2026 An opinion has put pressure on the CJEU to clarify a long-running grey area that could change the game for how drug makers secure supplementary protection certificates across Europe.
23 April 2026 The US pharma giant is spending up to $1 billion to build an end-to-end biosimilar platform and is counting on a decade of expiring biologic patents to make it pay off.
22 April 2026 Decision underscores a growing deference to parallel rulings and tighter control over duplicate patent challenges.
15 April 2026 The Danish pharma giant is turning to artificial intelligence as it faces patent expiry, falling shares and intensifying competition from Eli Lilly.
Get up-to-date information on all our publications and events
Get critical life sciences news direct to your inbox